Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Oncol. 2010 Oct;4(5):443-50. doi: 10.1016/j.molonc.2010.06.001. Epub 2010 Jun 9.

Targeting leukemic stem cells by breaking their dormancy.

Author information

1
HI-STEM (Heidelberg Institute for Stem Cell Technology and Experimental Medicine), Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany. marieke.essers@hi-stem.de

Abstract

Transient or long-term quiescence, the latter referred to as dormancy are fundamental features of at least some adult stem cells. The status of dormancy is likely a critical mechanism for the observed resistance of normal HSCs and leukemic stem cells (LSCs) to anti-proliferative chemotherapy. Recent studies have revealed cytokines such as Interferon-alpha (IFNα) and G-CSF as well as arsenic trioxide (As(2)O(3)) to be efficient agents for promoting cycling of dormant HSCs and LSCs. Most interestingly, such cell cycle activated stem cells become exquisitely sensitive to killing by different chemotherapeutic agents, suggesting that dormant LSCs in patients may be targeted by a sequential two-step protocol involving an initial activation by IFNα, G-CSF or As(2)O(3), followed by targeted chemotherapy.

PMID:
20599449
DOI:
10.1016/j.molonc.2010.06.001
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center